SEC Filing Summary: Predictive Oncology Inc. (POAI)
Business Context and Reporting Period
This Form 8-K was filed by Predictive Oncology Inc. (POAI) on June 11, 2025, reporting events occurring on June 9, 2025. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "POAI".
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, or debt. The only financial metric disclosed is the failure to meet the Nasdaq minimum stockholders' equity requirement of $2,500,000 as of the reporting date.
Material Changes
- Delisting Notice: On June 9, 2025, Nasdaq notified the Company that it failed to regain compliance with the minimum stockholders' equity requirement (Rule 5550(b)(1)).
- Compliance Plan Failure: The Company was unable to complete its previously submitted plan of compliance within the 180-day extension period.
- Appeal Filed: The Company has submitted a request for a hearing to the Nasdaq Hearings Panel to appeal the delisting determination.
Outlook, Risks, and Management Commentary
Management states it will continue to evaluate all available options to regain compliance. The appeal request stays the suspension of trading and the filing of Form 25-NSE pending the Panel's decision. The Panel has discretion to grant an exception to listing standards for up to 180 days, though there is no assurance the request will be accepted or that compliance can be maintained if granted. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of the appeal outcome.
Investor Verification Checklist
- Verify the current status of the appeal with the Nasdaq Hearings Panel.
- Confirm the Company's current stockholders' equity balance to assess the gap against the $2.5 million requirement.
- Monitor for the filing of Form 25-NSE, which would officially remove the stock from Nasdaq listing.
- Check for any subsequent announcements regarding a new compliance plan or capital raise efforts.